These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32276621)

  • 1. Post-intravitreal injection endophthalmitis secondary to Turicella otitidis: a case report.
    Mammo DA; Watson D; Armbrust KR
    BMC Ophthalmol; 2020 Apr; 20(1):142. PubMed ID: 32276621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative Corynebacterium macginleyi endophthalmitis.
    Ferrer C; Ruiz-Moreno JM; Rodríguez A; Montero J; Alió JL
    J Cataract Refract Surg; 2004 Nov; 30(11):2441-4. PubMed ID: 15519105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leuconostoc as a Cause of Endophthalmitis Post-intravitreal Injection of Ranibizumab.
    Damasceno NP; Horowitz SA; Damasceno EF
    Ocul Immunol Inflamm; 2016; 24(1):118-9. PubMed ID: 24749654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS.
    Arnett JJ; Brodowska K; Gallagher DS; Eller AW; Friberg TR; Anetakis AJ; Martel JN
    Retina; 2020 Sep; 40(9):1719-1723. PubMed ID: 31800459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, microbiological profile and treatment outcome of patients with Corynebacterium endophthalmitis: review of a decade from a tertiary eye care centre in southern India.
    Joseph J; Nirmalkar K; Mathai A; Sharma S
    Br J Ophthalmol; 2016 Feb; 100(2):189-94. PubMed ID: 26124461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial.
    Albrecht E; Richards JC; Pollock T; Cook C; Myers L
    Br J Ophthalmol; 2011 Oct; 95(10):1385-8. PubMed ID: 21289020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe
    Salceanu SO; Levy S; Cunningham R; Frimpong-Ansah K
    Indian J Ophthalmol; 2017 Nov; 65(11):1249-1251. PubMed ID: 29133669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACTINOMYCES NEUII ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION.
    Sahni S; Watson RM; Sheth VS
    Retin Cases Brief Rep; 2017 Summer; 11(3):281-282. PubMed ID: 27280342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.
    Bhatt SS; Stepien KE; Joshi K
    Retina; 2011 Nov; 31(10):2032-6. PubMed ID: 21659941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus cereus endophthalmitis following intravitreous bevacizumab injection.
    Kopel AC; Carvounis PE; Holz ER
    Ophthalmic Surg Lasers Imaging; 2008; 39(2):153-4. PubMed ID: 18435343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
    Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
    Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endophthalmitis following intravitreal injections.
    Irigoyen C; Ziahosseini K; Morphis G; Stappler T; Heimann H
    Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):499-505. PubMed ID: 22048244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of Microbiological Profile and Management Outcomes of Acute Endophthalmitis after Microincision Vitrectomy Surgery versus Intravitreal Injections.
    Kannan NB; Sen S; Mishra C; Lalitha P; Rameshkumar G; Rajan RP; Arumugam KK; Ramasamy K
    Ocul Immunol Inflamm; 2021 Jul; 29(5):838-844. PubMed ID: 31900009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.